NovaSight Announces Commercial Release of CureSight in the US

NovaSight Announces Commercial Release of CureSight in the US

December 16, 2022

NovaSight, a leading medical technology company, has announced that its innovative product, CureSight, is now commercially available in the United States beginning this month. CureSight received FDA approval back in October 2022.

CureSight is a non-invasive, wearable device that utilizes advanced machine-learning algorithms for the diagnosis and treatment of amblyopia (lazy eyes). The revolutionary eye-tracking based device aims to prevent pediatric vision loss with rapid visual assessment and innovative amblyopia (lazy eyes) treatment.

CureSight therapy is carried out while the child watches any streamed content of their choice on a user-friendly, eye tracking based device from the comfort of their home. Using a web portal, eye care professionals can discuss treatment results with patients and track their compliance with their treatment progress.

NovaSight also revealed that Drew Hopper has been named as the new Vice President of Sales and Marketing North America.

Mr. Hopper is an executive leader in the commercial sector with more than 20 years of sales and marketing experience, including ten years in the eye care industry. As VP Sales and Marketing for North America, Mr. Hopper will cultivate client relationships, select key opinion leaders (KOLs) to join NovaSight's scientific advisory board, support the business's efforts to obtain reimbursement by speaking with payers, and create, oversee, and sustain sales and marketing initiatives.

“We are excited to bring CureSight into the U.S. market, and to begin the process of building out our U.S. based commercial capabilities,” said Mr. Hopper.

A Physician Early Adopter’s Program, a dedicated CureSight Monitoring Center, and three unique CPT codes will assist U.S. eye care providers in integrating CureSight into their practices.

● Starting this month, a select group of Physician's Early Adopter Program participants will start recommending CureSight to their amblyopic patients. As medical coverage expands, the next phase of U.S. commercialization will start in the first half of 2023 with an official launch that will involve a group of hundreds of doctors who have already signed up for the CureSight Referral Program.

● In order to provide complete physician and patient support, including compliance monitoring, troubleshooting, billing, and technical support, CureSight treatment referrals are transmitted via portal to a nationwide Monitoring Center run by practicing ophthalmologists and supported by a team of certified ophthalmic professionals and patient engagement specialists.